Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is an uncurable haematological malignancy and is associated with significant infection morbidity. Bruton’s tyrosine-kinase inhibitors (e.g., ibrutinib) have improved disease outcomes, but severe infections and poor i…